clinical trial · NCT07328217
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Advanced Solid TumorsGW5282GW5282
brief summary
This is a phase 1/2, open-label, multicenter study assessing the safety, tolerability, pharmacokinetics and efficacy of GW5282 in participants with locally advanced or metastatic solid tumors. This study comprised of a dose escalation phase to determine the MTD and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of GW5282.
started
Jan 29, 2026
primary completion
Dec 1, 2028
completion
Jun 1, 2029
last updated
Feb 11, 2026
official title
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of GW5282 in Participants With Advanced Solid Tumors (BEI-DOU2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol